Shopping Cart 0
Cart Subtotal
USD 0

Human Longevity Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Human Longevity Inc (HLI) is a genomics-based technology company that develops sequenced genomes and phenotypic database. The company's discovery capabilities include streamlining drug development, rescuing and repurposing drugs from failed clinical trials and discovery of biomarker and companion diagnostics. It focuses on therapeutic areas such as cancer, diabetes and obesity, heart and liver diseases, neurodegenerative and neurovascular disease, metabolic disease, and dementia. The company supports predictive, preventive and personalized care including the cancer analysis, integrated health analysis, newborn screening and rare, undiagnosed diseases through its genome sequencing and analysis. HLI is headquartered in San Diego, California, the US.

Human Longevity Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Human Longevity Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Human Longevity Inc, Medical Devices Deals, 2012 to YTD 2018 10

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Human Longevity Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 12

Venture Financing 13

Celularity Raises USD250 Million in Venture Financing 13

Celularity Raises Funds through Series A Financing 15

Human Longevity Raises USD 70 Million In Venture Financing 16

Partnerships 17

Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 17

Human Longevity Enters into Agreement with Merck 19

Cypher Genomics Enters into Research Agreement with Clinic for Special Children 20

Cypher Genomics Enters into Co-Development Agreement with Celgene 21

Cypher Genomics Enters into Co-Promotion Agreement with Illumina 22

Licensing Agreements 23

Human Longevity Enters into Licensing Agreement with Celgene Cellular Therapeutics for PSC-100 23

Acquisition 24

Human Longevity Acquires LifebankUSA from Celgene Cellular Therapeutics 24

Human Longevity Inc-Key Competitors 25

Human Longevity Inc-Key Employees 26

Human Longevity Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Corporate Communications 28

Jul 13, 2018: Human Longevity Appoints Dr. David Karow, MD, Ph.D., As Interim Chief Executive Officer 28

Mar 19, 2018: Human Longevity, Inc. Hires Former Ancestry Executive, Scott Sorensen, As New Chief Technology Officer 29

Dec 01, 2017: Human Longevity Announces Executive Leadership Changes: Co-Founder J. Craig Venter, Ph.D. is Reappointed as CEO 30

May 25, 2017: Saturnino Fanlo Joins Human Longevity As Chief Financial Officer 31

May 02, 2017: Human Longevity Enhances Senior Leadership Team, Making Key Hires to Strengthen Commercialization and Operations 32

Jan 04, 2017: Human Longevity Hires Cynthia Collins, Healthcare Industry Leader, as New Chief Executive Officer 34

Legal and Regulatory 36

Apr 18, 2018: Human Longevity Clinical Labs Receives Accreditation from College of American Pathologists 36

Government and Public Interest 37

Feb 26, 2018: Human Longevity Scientists Publish Paper Diving Deeper into Non-Coding Genome Which Represents 98% of the Human Genome 37

Feb 05, 2018: New Metabolomic and Genomic-Informed Study Shows Use of Acetaminophen Has Unexpected Effects on Regulation of Sex Hormones 38

Product News 39

Aug 21, 2017: Celularity Accelerates Breakthrough Placental Discovery & Therapeutic Platform 39

Jul 03, 2017: Human Longevity Researchers Develop New Algorithm to Rapidly and Accurately Predict HLA Types Using Illumina Next Generation Sequencing Technology 40

Mar 28, 2018: Human Longevity Launches New Health Nucleus Products With Membership Component 41

Mar 06, 2017: In Largest Whole Genome Sequence Analysis Study, Human Longevity-Led Team Identifies Common-to-Rare Variants in the Human Blood Metabolome 42

Other Significant Developments 43

May 11, 2017: Human Longevity, Inc. Launches Pilot Program, Health Nucleus X 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Human Longevity Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Human Longevity Inc, Pharmaceuticals & Healthcare, Key Facts 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Human Longevity Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Human Longevity Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Human Longevity Inc, Medical Devices Deals, 2012 to YTD 2018 10

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 12

Celularity Raises USD250 Million in Venture Financing 13

Celularity Raises Funds through Series A Financing 15

Human Longevity Raises USD 70 Million In Venture Financing 16

Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 17

Human Longevity Enters into Agreement with Merck 19

Cypher Genomics Enters into Research Agreement with Clinic for Special Children 20

Cypher Genomics Enters into Co-Development Agreement with Celgene 21

Cypher Genomics Enters into Co-Promotion Agreement with Illumina 22

Human Longevity Enters into Licensing Agreement with Celgene Cellular Therapeutics for PSC-100 23

Human Longevity Acquires LifebankUSA from Celgene Cellular Therapeutics 24

Human Longevity Inc, Key Competitors 25

Human Longevity Inc, Key Employees 26

Human Longevity Inc, Other Locations 27

Human Longevity Inc, Subsidiaries 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Human Longevity Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Human Longevity Inc (HLI) is a genomics-based technology company that develops sequenced genomes and phenotypic database. The company's discovery capabilities include streamlining drug development, rescuing and repurposing drugs from failed clinical trials and discovery of biomarker and companion diagnostics. It focuses on therapeutic areas such as cancer, diabetes and obesity, heart and liver diseases, neurodegenerative and neurovascular disease, metabolic disease, and dementia. The company supports predictive, preventive and personalized care including the cancer analysis, integrated health analysis, newborn screening and rare, undiagnosed diseases through its genome sequencing and analysis. HLI is headquartered in San Diego, California, the US.

Human Longevity Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Human Longevity Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Human Longevity Inc, Medical Devices Deals, 2012 to YTD 2018 10

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Human Longevity Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 12

Venture Financing 13

Celularity Raises USD250 Million in Venture Financing 13

Celularity Raises Funds through Series A Financing 15

Human Longevity Raises USD 70 Million In Venture Financing 16

Partnerships 17

Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 17

Human Longevity Enters into Agreement with Merck 19

Cypher Genomics Enters into Research Agreement with Clinic for Special Children 20

Cypher Genomics Enters into Co-Development Agreement with Celgene 21

Cypher Genomics Enters into Co-Promotion Agreement with Illumina 22

Licensing Agreements 23

Human Longevity Enters into Licensing Agreement with Celgene Cellular Therapeutics for PSC-100 23

Acquisition 24

Human Longevity Acquires LifebankUSA from Celgene Cellular Therapeutics 24

Human Longevity Inc-Key Competitors 25

Human Longevity Inc-Key Employees 26

Human Longevity Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Corporate Communications 28

Jul 13, 2018: Human Longevity Appoints Dr. David Karow, MD, Ph.D., As Interim Chief Executive Officer 28

Mar 19, 2018: Human Longevity, Inc. Hires Former Ancestry Executive, Scott Sorensen, As New Chief Technology Officer 29

Dec 01, 2017: Human Longevity Announces Executive Leadership Changes: Co-Founder J. Craig Venter, Ph.D. is Reappointed as CEO 30

May 25, 2017: Saturnino Fanlo Joins Human Longevity As Chief Financial Officer 31

May 02, 2017: Human Longevity Enhances Senior Leadership Team, Making Key Hires to Strengthen Commercialization and Operations 32

Jan 04, 2017: Human Longevity Hires Cynthia Collins, Healthcare Industry Leader, as New Chief Executive Officer 34

Legal and Regulatory 36

Apr 18, 2018: Human Longevity Clinical Labs Receives Accreditation from College of American Pathologists 36

Government and Public Interest 37

Feb 26, 2018: Human Longevity Scientists Publish Paper Diving Deeper into Non-Coding Genome Which Represents 98% of the Human Genome 37

Feb 05, 2018: New Metabolomic and Genomic-Informed Study Shows Use of Acetaminophen Has Unexpected Effects on Regulation of Sex Hormones 38

Product News 39

Aug 21, 2017: Celularity Accelerates Breakthrough Placental Discovery & Therapeutic Platform 39

Jul 03, 2017: Human Longevity Researchers Develop New Algorithm to Rapidly and Accurately Predict HLA Types Using Illumina Next Generation Sequencing Technology 40

Mar 28, 2018: Human Longevity Launches New Health Nucleus Products With Membership Component 41

Mar 06, 2017: In Largest Whole Genome Sequence Analysis Study, Human Longevity-Led Team Identifies Common-to-Rare Variants in the Human Blood Metabolome 42

Other Significant Developments 43

May 11, 2017: Human Longevity, Inc. Launches Pilot Program, Health Nucleus X 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Human Longevity Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Human Longevity Inc, Pharmaceuticals & Healthcare, Key Facts 2

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Human Longevity Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Human Longevity Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Human Longevity Inc, Medical Devices Deals, 2012 to YTD 2018 10

Human Longevity Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 12

Celularity Raises USD250 Million in Venture Financing 13

Celularity Raises Funds through Series A Financing 15

Human Longevity Raises USD 70 Million In Venture Financing 16

Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 17

Human Longevity Enters into Agreement with Merck 19

Cypher Genomics Enters into Research Agreement with Clinic for Special Children 20

Cypher Genomics Enters into Co-Development Agreement with Celgene 21

Cypher Genomics Enters into Co-Promotion Agreement with Illumina 22

Human Longevity Enters into Licensing Agreement with Celgene Cellular Therapeutics for PSC-100 23

Human Longevity Acquires LifebankUSA from Celgene Cellular Therapeutics 24

Human Longevity Inc, Key Competitors 25

Human Longevity Inc, Key Employees 26

Human Longevity Inc, Other Locations 27

Human Longevity Inc, Subsidiaries 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Human Longevity Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.